Published in final edited form as:

Acc Chem Res. 2013 November 19; 46(11): 2416–2426. doi:10.1021/ar3003267.

The Increasingly Complex Mechanism of HMG-CoA Reductase

BRANDON E. HAINES¹, OLAF WIEST¹, and CYNTHIA V. STAUFFACHER²

OLAF WIEST: owiest@nd.edu; CYNTHIA V. STAUFFACHER: cstauffa@purdue.edu

¹Department of Chemistry and Biochemistry, Notre Dame University, Notre Dame, Indiana 46556, United States

²Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, United States

CONSPECTUS

The seven decades of research on the mechanism of HMG-CoA Reductase (HMGR) provided a detailed reaction pathway for what is one of the most biomedically important and mechanistically most complex enzymes. HMGR is the target of statins that are prescribed to improve the quality of life of millions of people worldwide and, more recently, has been identified as a target for the development of antimicrobial agents.

The impact of advances in diverse research areas, such as molecular biology and computational chemistry, are reflected in the maturation of mechanistic proposals for HMGR. Thus, the development of state-the-art methods in enzyme mechanism research can be traced by following the development of the HMGR mechanism. Similarly, the questions raised about these mechanism proposals reflect the limitations of these methods.

Correspondence to: OLAF WIEST, owiest@nd.edu; CYNTHIA V. STAUFFACHER, cstauffa@purdue.edu.

The authors declare no competing financial interest.

The mechanism of HMGR, a four-electron oxidoreductase, has been uncovered to be unique and far more complex than originally thought. The reaction contains multiple chemical steps, coupled to large-scale domain motions of the homodimeric enzyme. The first proposals for the HMGR mechanism were based on kinetic and labeling experiments, drawing analogies to the mechanism of known dehydrogenases. Advances in molecular biology and bioinformatics enabled site-directed mutagenesis experiments and protein sequence analysis which identified catalytically important glutamate, aspartate, and histidine residues that in turn generated new and more complicated mechanistic proposals.

With the development of protein crystallography, HMGR crystal structures were solved to reveal the spatial organization of the active site with an unexpected lysine residue lying at its center. The multitude of crystal structures led to more and more complex mechanistic proposals but the inherent limitations of the protein crystallography left a number of questions unresolved. For example, the proposed mechanisms change based on the protonation state of the active site glutamate residue, which cannot be clearly determined from the crystal structures.

As computational analysis of large biomolecules become more feasible, application of methods such as hybrid quantum mechanics/molecular mechanics (QM/MM) calculations to the HMGR mechanism have led to the most detailed mechanistic proposal yet. As these methodologies continue to improve, their power to study enzyme mechanism in conjunction with protein crystallography is enormous. Nevertheless, even the most current mechanistic proposal is yet incomplete due to limitations of the current computational methodologies. Thus, HMGR serves as a model for how combination of increasingly sophisticated experimental and computational methods can elucidate very complex enzyme mechanisms.

Introduction

Methods for the study of complex enzyme mechanisms, and with them the ever-increasing level of detail accessible, are constantly evolving. 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is an excellent example of the constant revisitation, revision, and refinement of a complex mechanism which has taken place over seven decades of studies and employed numerous methods. HMGR is arguably the most well-known enzyme of the eukaryotic mevalonate pathway for isoprenoid biosynthesis because of its importance in the biomedical fields as a target for cholesterol lowering drugs called statins.¹⁻³ In effect, the extraordinary health impact of the statins has somewhat overshadowed the fascinating mechanism of HMGR.

The mevalonate pathway is found predominantly in eukaryotes, but also in a few prokaryotes. Most eubacteria depend on a different pathway for isoprenoid biosynthesis called the non-mevalonate pathway or deoxyxylulose 5-phosphate pathway, which is also found in plants.^{4,5} In eukaryotes, the mevalonate pathway produces the precursor molecule isopentenyl 5-diphosphate from acetyl-CoA, which feeds into the production of important biomolecules and natural products such as farnesyl phosphate, dolichol and cholesterol.^{5,6} The complete mevalonate pathway and its enzymes are indexed in Figure 1.⁶ More recently, the essentiality of the mevalonate pathway has been demonstrated in a subset of pathogenic

bacteria, such as MRSA, VRE, and SPn,^{7–9} inspiring efforts to find small molecule inhibitors of the mevalonate pathway enzymes for treatment against infection.^{10–12}

As a result of its central position in the metabolic network, HMGR is highly regulated and serves as the point of feedback control for the mevalonate pathway.^{13,14} Upon competitive inhibition of the human HMGR, expression of LDL receptors is increased and therefore clearance of cholesterol-LDL is increased.^{15,16} Statins bind tightly to the human HMGR, with inhibition constants in the nanomolar range¹⁷, and are, therefore, commonly prescribed to treat hypercholesterolemia and reduce the risk of cardiovascular disease.^{1,2} However, the drugs bind with inhibition constants in the micromolar range and therefore less tightly to the HMGRs of pathogenic bacteria.^{18,19} This observation is explained in part by protein sequence alignments of the known HMGR enzymes. Two evolutionarily divergent classes of HMGRs that split roughly by eukaryotes (Class I) and prokaryotes (Class II) were discovered.^{20,21} The Class I HMGRs are generally membrane-bound with a transmembrane domain and a catalytic domain. Initially, all of the known HMGR enzymes belonged to Class I and were difficult to express and purify because of their membrane-bound nature. In contrast, the Class II enzymes are cytosolic and lack the transmembrane domain of the Class I enzymes.¹⁴ The first Class II HMGR was discovered from a eubacterium, *Pseudomonas mevalonii* (*Pm*HMGR), although the classes had not yet been defined at the time. It remained the only known Class II enzyme until the modern sequencing efforts uncovered additional examples. *Pm*HMGR was found to possess qualities desirable for mechanistic and structural studies in that it is soluble, can be induced in large quantities, and forms relatively robust crystals.^{22,23} Thus, *Pm*HMGR took center stage as a model HMGR for studying the enzymatic reaction mechanism.

The structures of the catalytic domains within the classes are well conserved. Sequence identities within Class I HMGRs are ~60%, while sequence identities within Class II enzymes are ~50%.²⁰ However, the sequences across classes are only weakly conserved, although they possess similar folds and conserved active site residues as shown in the sequence alignment of selected examples in Figure 2.¹⁴ The sequence identities between classes are only ~14–20%, and the differences are manifested in distinctive structural features.²⁰ The most interesting of these structural features is the conserved “*cis*-loop” motif found only in the Class I enzymes, which contains a *cis*-peptide and forms part of the HMG-CoA binding pocket.^{24,25} Other differences between the classes include the stereochemistry of the chemical reaction^{25–28} and, in some cases, cofactor specificity.^{14,29} The structural differences between classes are sufficient to explain the preference of statins for Class I enzymes. It has been suggested that modified statins would be a logical starting point to find Class II selective inhibitors.^{17,19}

The overall reaction mechanism of HMGR presents a case that is arguably as remarkable in enzymology as the enzyme is biomedically relevant. It is a rare example of a four-electron oxidoreductase that uses two molecules of the cofactor nicotinamide adenine dinucleotide (NAD(P)) in the reversible conversion of (*S*)-HMG-CoA and (*R*)-mevalonate.³⁰ The reaction is thought to proceed through two intermediates, mevaldyl-CoA and mevaldehyde, and consist of two hydride transfer steps, a cofactor exchange step, and a hemithioacetal decomposition step, as shown in Figure 3. The enigmatic aldehyde intermediate has never

been detected experimentally, leading to the hypothesis that the hemithioacetal is the prominent reaction intermediate.^{31–35} This theory is further supported by a crystal structure with electron density for a tetrahedral hemithioacetal analogue in the active site and free energy calculations performed on the ternary complexes of a proposed reaction pathway.^{36,37} However, this poses the question of at what point the aldehyde is formed since the hemithioacetal is presumably unreactive towards NAD(P)H.

The reaction mechanism is further complicated by the cofactor exchange step. In *Pm*HMGR crystal structures with one or no ligands present there is no electron density for the C-terminal 50 residues of the enzyme, which is known as the flap domain.²³ When both ligands are present, electron density for the flap domain is found positioned over the active site in a three α -helix bundle making direct contacts with both substrate and cofactor as shown in Figure 4. This suggests that the movements of the flap domain are somehow involved in the process of substrate and cofactor binding.²⁸ It stands to reason then that some degree of flap domain motion must occur between the hydride transfer reactions in order to exchange the expended cofactor. This process must have an impact on the enzyme intermediate states and may contribute to the elusiveness of the aldehyde intermediate. Thus, the reaction mechanism of HMGR has revealed itself as a complex and delicately controlled reaction, which can only be appropriately described in a dynamic context that considers both structural and chemical elements.

In this account, we trace the efforts to elucidate the mechanism of HMGR involving a progression of mechanistic proposals over time and highlighting the connections between these proposals and the research tools available at the time they were proposed. The culmination of the discussion will arrive at the present time with a demonstration of how powerful the combination of x-ray crystallography and computational methods can be in enzymology. The connection between HMGR mechanistic proposals and research methodologies begins when early kinetic studies, heavy-atom labeling studies, and site-directed mutagenesis studies revealed a set of catalytically important residues and information on the reaction intermediates.^{22,31,39–41} Then, crystal structures have provided complete spatial resolution of the active site, a full set of catalytic residues, and evidence for the impact of the flap domain on the reaction.^{28,37,38} As the mechanism was being formulated, structures of the Class I human HMGR suggested a conflicting mechanism and brought the potential effects of the class differences to light.^{14,24,25} Lastly, computational methods have provided a partial energetic description of the reaction and visualization of intermediate states that cannot be obtained by experiment.³⁶

The early HMGR mechanism proposals and the discovery of *Pm*HMGR

Before the discovery of *Pm*HMGR, only Class I enzymes were known, but they were hard to study because they are membrane bound. Most research was performed on the yeast HMGR, which had been used to study the curious absence of the aldehyde in free form during the reaction that was inconsistent with the proposed reaction pathway and to explore the possibility of a hemithioacetal intermediate.^{31,34,35,42} Qureshi *et al.* described the stereoselective chemical mechanism of hydride transfer and hemithioacetal breakdown, implicating unspecified acidic and basic residues.³⁴ Shortly afterwards, Veloso *et al.*

expanded the mechanism using pH dependent kinetic analyses to specify an acidic residue and a cationic histidine as the catalytic residues. The reduction steps were likened to the mechanism of the classic dehydrogenases and were presented as two separate reactions as shown in Figure 5.⁴² However, complicated kinetics led to uncertainty around the ligand binding mechanism and identification of the rate determining step. It was implied that the protonation state of the catalytic histidine had an effect on which redox form of the cofactor would bind.⁴²

Pseudomonas mevalonii was found among a group of organisms capable of living on mevalonate as their sole source of carbon.^{43,44} Growth of the organism on mevalonate was found to produce large quantities of *Pm*HMGR for the initiation of mevalonate catabolism through a reversal of the mevalonate pathway.⁴⁴ As the only known Class II enzyme and therefore the only available soluble enzyme, *Pm*HMGR was identified as a good model HMGR for mechanistic studies.²² It had been shown previously that several Class I HMGRs are inactivated through cysteine modification by sulfhydryl reagents such as N-ethylmaleimide (NEM).^{32,33,45} *Pm*HMGR is also susceptible to sulfhydryl reagents, and it was shown that NEM prevents the enzyme from catalyzing all reactions in either the forward or the backward directions.²² It was speculated that a cysteine could be a catalytically important residue in the active site or important for substrate binding. To test this hypothesis either or both of the two cysteines of *Pm*HMGR were mutated to alanine residues in site-directed mutagenesis (SDM) experiments.⁴⁰ The mutants catalyzed the reactions at the same level of efficiency as the wild-type enzyme and did not affect substrate binding. It was therefore concluded that the cysteine residue responsible for the inactivation must be causing an irreversible conformational change upon modification and is not an essential active site residue.⁴⁰

Based on these results, the mechanism shown in Figure 5 was revisited. Protein sequence alignment of the known HMGRs identified conserved acidic and histidine residues. The residues that were found to be essential for *Pm*HMGR activity through SDM experiments were Glu83 and His381.^{39,41} An attempt to confirm the identity of these catalytically important residues in a mammalian enzyme revealed an additional conserved acidic residue, an aspartate (Asp766 of the Syrian hamster HMGR), that inactivated the enzyme upon mutation.⁴⁶ By investigating the effects of mutating these catalytically important residues on the individual half reactions of the enzyme, a new mechanism shown in Figure 6 was proposed.⁴⁷ It was found that the glutamate and histidine mutants are capable of catalyzing one or more of the half reactions, while the aspartate mutant had no activity in catalyzing either of the half reactions.⁴⁷ Therefore, the authors proposed that the catalytic acidic residue was the aspartate even though this conclusion was inconsistent with the studies on the bacterial HMGR, which concluded that the catalytic acidic residue is Glu83.

The Crystal Structures of *Pm*HMGR

The next step in the evolution of our understanding of the HMGR mechanism was the determination of the first crystal structure, *Pm*HMGR. It revealed the enzyme as an obligate dimer with the active site at its interface.^{23,38,46} Each monomer consists of three domains: the large domain, the small domain, and the C-terminal flap domain. The large domain (1–

108 and 220–375) is centered on a 24 residue hydrophobic α -helix surrounded by a triangle of three mixed α/β walls. The binding site for HMG-CoA has a well-defined pocket for the HMG moiety, whereas the CoA portion is positioned in a shallow surface groove, making few direct hydrogen bonds with the enzyme. The adenine ring of CoA is tacked down by a surface arginine residue, while the CoA phosphate groups contact the enzyme through water-mediated hydrogen bonds.³⁷ The small domain (110–215) binds NADH with a nonclassical dinucleotide fold, comprised of a four-strand anti-parallel β sheet with two crossover helices on one side. A conserved loop containing the DAMG sequence connects the third strand and the second helix, which is analogous to the G-rich loop in the classic dinucleotide-binding domain.²⁸ The cofactor is bound such that it is stretched out on the enzyme with the nicotinamide ring inserted into the active site pocket parallel to the HMG moiety of the substrate. This positioning of the cofactor is unique because it is not positioned over or under the substrate in the active site which might be due to the need to exchange during the reaction.

Initial attempts to solve the crystal structure of the ternary complex were foiled by the discovery that HMGR had enzyme activity in the crystal form. However, nonproductive ternary complexes with the oxidized form of the cofactor produced a model complex for this state. This structure contains electron density for the flap domain (377–428), which was not previously seen in the apo enzyme, ordered over the active site in three α helices connected by short loops.²⁸ The first helix is connected to the central α helix of the large domain by a hinge region (375–377) that likely plays a role in substrate binding.²⁸ The flap domain contacts occur between this first helix and the small domain of the second monomer as well as bound substrate and cofactor. Ordering of the flap domain aligns hydrophobic residues to form a pocket at the inner face of helix 1 that has been suggested to provide protection of the reaction center from the solvent.^{28,38} The closing of the flap domain also has implications for catalytic activity as it brings His381 into the active site within reach of the sulfur atom of HMG-CoA consistent with its proposed role in the HMGR reaction.^{28,47} The various domains, ligands bound at the dimer interface, and active site residues are shown in the crystal structure in Figure 7.

In addition to the essential residue Glu83, the *Pm*HMGR crystal structures also revealed the positions of the conserved residues Asp283, Lys267, and Asn271 in the active site. The discovery of Lys267 centrally located in the active site near Glu83 and Asp283 was surprising because it had not been previously implicated in catalysis. SDM experiments subsequently confirmed that it is indeed important for enzyme activity.²⁸ The crystal structures show the presumably protonated Lys267 hydrogen bonding with the thioester carbonyl of the substrate, which led to the proposal of a revised mechanism shown in Figure 8. Here, Lys267 polarizes the substrate carbonyl for each hydride transfer and acts as the general acid to protonate mevalonate at the end of the reaction. A proton relay is suggested where Glu83 is close enough to assist in mevaldyl-CoA decomposition and subsequently passes this proton to Lys267. An anionic Asp283 and multiple other residues support the position of Lys267 through secondary hydrogen bonds. Consistent with the previously proposed mechanisms, His381 is positioned to protonate the CoA thiolate anion after the first hydride transfer.²⁸

Crystal structures of the Human HMGR and the protonation state of the catalytic acidic residue

In the next set of studies, Istvan et al. solved the crystal structure of the human HMGR catalytic domain and observed a similar set of conserved catalytic residues in the active site.²⁵ The human HMGR crystal forms a tetramer with obligate dimers that assemble similarly to those of *Pm*HMGR, despite their lack of sequence identity.¹⁴ However, the active site is formed from very different secondary structure elements, in particular the “cis loop” of the human HMGR that runs along one side of the active site positioning the catalytically important lysine residue, Lys735.^{14,24} Differences in the positions of the catalytic residues between the human HMGR and the nonproductive *Pm*HMGR complexes led to another modification of the proposed mechanism for the human HMGR, which is shown in Figure 9. In this mechanism, the acidic residue, Glu559, which is analogous to Glu83, is protonated. The authors speculate that the negatively charged aspartate residue, Asp767, which is analogous to Asp283 in *Pm*HMGR, is close enough to Glu559 to affect its pK_a .²⁴ This change results in the proposal of a different chemical mechanism in which Glu559 and Lys735 form an oxyanion hole to stabilize the reaction intermediates after hydride transfer, and Glu559 is identified as the general acid/base for the reaction. Asp767 supports the position of Lys691 and exerts some control over the protonation state of Glu559 while the catalytic histidine, H866, performs the same function as previously discussed.²⁴ The difference between the mechanisms shown in Figures 8 and 9 thus hinges on the protonation state of Glu83/Glu559, which of course cannot be unequivocally assigned based on the crystal structures.

Istvan et al. proposed that the different mechanisms for the enzymes could arise from class-related differences.²⁴ However, the structural differences in the active site residues are subtle, and further studies were needed to test this hypothesis. Recently, computational methods were employed to investigate the effect of the protonation state of Glu83 on the *Pm*HMGR mechanism.³⁶ Direct calculation of the pK_a of a given residue in a given environment is difficult and most likely not accurate enough to unambiguously assign the protonation state, but quantum mechanical calculations allow for the investigation of the effect of such a variable on a given chemical reaction. Reaction barriers and energies calculated for both protonation states suggest that the first hydride transfer proceeds along a lower energy pathway when Glu83 is protonated.³⁶ When Glu83 is deprotonated, both the reaction barrier and the reaction energy are more than 10 kcal/mol higher than when Glu83 is protonated. The structures show that Glu83 easily acts as an acid/base during the reaction, but Lys267 cannot perform this function in either case. In fact, the computational models predict that the *Pm*HMGR active site environment with Glu83 deprotonated cannot stabilize the experimentally observed hemithioacetal intermediate. In these calculations, the carbon-sulfur bond of the model hemithioacetal lengthens and it dissociates, which is inconsistent with the available experimental results.^{35–37} These calculations were performed on a Class II enzyme and affirm the mechanism that was proposed for a Class I enzyme therefore it is likely that a general mechanism exists for all HMGRs.

Reaction Intermediates and Cofactor Exchange

Mevaldyl-CoA generated *in situ* is an active substrate of the enzyme and, in the presence of cofactor, is quickly converted to products in the crystal.^{22,35} The HMG-CoA analogue, dithio-HMG-CoA, was initially thought to be a competitive inhibitor of HMGR.⁴⁸ In the complex of *Pm*HMGR with dithio-HMG-CoA and NADH, designed to capture the enzyme-substrate complex, this inhibitor was found to be a slow substrate.³⁷ This structure, shown in Figure 11, has electron density for a tetrahedral dithiohemiacetal species in the active site, which is analogous to the hemithioacetal intermediate postulated to form from the natural substrate.³⁷ It not only reveals specific contacts between the enzyme and intermediate, but it also provides clues about the structural changes that occur along the reaction coordinate. A hydrogen bonding network was identified that includes the residues of the flap domain, a Class II conserved serine residue (Ser85), and the amide group closest to the sulfur of HMG-CoA. Ser85 was found to be critical for enzyme activity through SDM experiments, confirming the involvement of yet another remote residue in the reaction.³⁷ The structure shows how changes at the reaction center propagate to changes in the hydrogen bonding patterns of the aforementioned groups which may potentially act to govern processes such as flap domain opening and closing. Comparing this intermediate structure to the initial HMG-CoA binary complex, nonproductive HMG-CoA/NAD⁺ ternary complex as well as molecular dynamics simulations of the HMG-CoA/NADH ternary complex indicates that a major distortion of the substrate, a 180° flip of its first amide bond through interactions with Ser85 and His381, is structurally important to the reaction pathway.

The fact that mevaldehyde is not detected during the reaction still adds to the remaining mechanistic ambiguity. The aldehyde has not been captured in a crystal structure and was not observed in isotope dilution and semicarbazide trapping experiments.^{31–33,49} In solution, equilibration of CoA thiols, aldehydes, and their corresponding hemithioacetals is known to be rapid⁵⁰, so one might expect the formation of an appreciable amount of aldehyde with the accumulation of the enzyme-hemithioacetal complex. It appears unlikely that the aldehyde stays bound to the enzyme during the reaction because K_m values for mevaldehyde are in the μM – mM range which should lead to dissociation upon solvent exposure of the active site. It might be beneficial for the efficiency of the enzyme to develop a mechanism to protect the aldehyde from solvent because mevaldehyde is significantly hydrated in H₂O and D₂O.⁴²

Inclusion of the cofactor exchange step provides the conceptual framework to expand the mechanism and explain these experimental observations. Based on the available data, there are two steps along the reaction pathway for cofactor exchange to reasonably occur, either before or after hemithioacetal decomposition. If cofactor exchange occurs after hemithioacetal breakdown then presumably the aldehyde would dissociate and be detected. But if cofactor exchange occurs before hemithioacetal breakdown the aldehyde would never be exposed to solvent, which is consistent with those observations above. This would indicate that hemithioacetal breakdown is *slower* than cofactor exchange. Free energy calculations offer some support for this notion, indicating that the enzyme thermodynamically prefers mevaldyl-CoA to mevaldehyde.³⁶ QM/MM structures along the hydride transfer coordinate suggest a mechanism by which this could occur. An electrostatic

interaction between the oxidized NAD cofactor and deprotonated Glu83 may contribute to slowing the base-catalyzed decomposition of the hemithioacetal.^{36,42}

Revised Mechanism

The latest proposal for the mechanism of HMGR and the structural changes involved is shown in Figure 12. HMG-CoA and NADH bind to the active site and the flap domain becomes ordered. The thioester of HMG-CoA is reduced and the oxyanion is stabilized by proton donor Glu83 and hydrogen bond donor Lys267. The hemithioacetal persists while the flap domain opens and the oxidized NAD⁺ cofactor dissociates. Once another molecule of reduced NADH cofactor binds to the active site the flap domain reorders. Then Glu83 assists in the base-catalyzed decomposition of the hemithioacetal to produce mevaldehyde and the CoA thiolate anion, which is then protonated by the cationic His381. CoASH is held in place by Ser85 and His381 while mevaldehyde is reduced and the oxyanion is again stabilized by proton donor Glu83 and hydrogen bond donor Lys267. The flap domain becomes disordered and the product mevalonate, CoASH, and oxidized cofactor are released.

Computational methods have afforded a structural and energetic description of the two hydride transfer steps. The transition structures generated with QM/MM methods are shown in Figure 13. The reaction energies for both conversions are estimated to be approximately thermoneutral which is consistent with the calculated transition states for hydride transfer. The rate determining step of the reaction has not been experimentally determined, however. The calculations rule out the mevaldehyde reduction step because its barrier is lower than the thioester reduction step by almost 3 kcal/mol. The energy barrier calculated for the first hydride transfer step, 21.8 kcal/mol, is consistent with the experimentally determined rate constant which places the reaction on the order of 1/s-1/min.

Conclusions and Open Questions

The combined use of kinetic studies, x-ray crystallographic studies, site-directed mutagenesis and, more recently, computational methods have provided iterative refinement of our understanding of the mechanism of HMGR, as shown in the subsequently more complex mechanistic proposals summarized in Figures 3, 5, 6, 8, 9, and 12. The most recent proposal rationalized the available experimental results, including the importance of remote residues. However, even this mechanistic proposal does not completely describe the exceptionally complex reaction mechanism of HMGR. For example, there is no structural or energetic description of the cofactor exchange step, so the rate-determining step is still unknown. The cofactor exchange step includes the structural mechanism for opening and closing of the flap domain and an energetic description of substrate and cofactor binding. Hinge residues have been identified, but the structure of the open flap could not be resolved in the apo-structure of HMGR. Although a dependence on substrate and cofactor binding is implicated, the forces that govern the flap movement are also unknown.

Further experimental and computational studies along the entire reaction coordinate will be necessary to determine the identity of the rate determining step and to confirm or refute the hypotheses developed here about the relationship between the intermediate states including the role of the observed interactions between Ser85, His381, and coenzyme A. The

possibility of an alternate chemical mechanism also must be considered. For example, it is possible the aldehyde intermediate does not actually form and the reaction proceeds through a substitution type mechanism. Nonetheless, the combination of structural biology and computational chemistry has thus far developed the HMGR mechanism to a new level of detail. This combination of methods has the capacity to answer the questions outlined above concerning the HMGR mechanism and to also uncover new questions to challenge the present knowledge of the mechanism. In all, the HMGR mechanism can serve as a model for how increasingly sophisticated methods can, in combination, elucidate even very complex mechanisms.

References

1. Grundy SM. HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia. *N Engl J Med.* 1988; 319:24–33. [PubMed: 3288867]
2. Singh N, Tamariz J, Chamorro G, Medina-Franco JL. Inhibitors of HMG-CoA Reductase: Current and Future Prospects. *Mini-Rev Med Chem.* 2009; 9:1272–1283. [PubMed: 19929805]
3. Tobert JA. Lovastatin and Beyond: The History of the HMG-CoA Reductase Inhibitors. *Nat Rev Drug Discovery.* 2003; 2:517–526.
4. Eisenreich W, Bacher A, Arigoni D, Rohdich F. Biosynthesis of Isoprenoids via the Non-mevalonate Pathway. *Cell Mol Life Sci.* 2004; 61:1401–1426. [PubMed: 15197467]
5. Lange BM, Rujan T, Martin W, Croteau R. Isoprenoid Biosynthesis: The Evolution of Two Ancient and Distinct Pathways Across Genomes. *Proc Natl Acad Sci U S A.* 2000; 97:13172–13177. [PubMed: 11078528]
6. Miziorko HM. Enzymes of the Mevalonate Pathway of Isoprenoid Biosynthesis. *Arch Biochem Biophys.* 2011; 505:131–143. [PubMed: 20932952]
7. Skaff DA, Ramyar KX, McWhorter WJ, Barta ML, Geisbrecht BV, Miziorko HM. Biochemical and Structural Basis for Inhibition of *Enterococcus faecalis* Hydroxymethylglutaryl-CoA Synthase, mvaS, by Hymeglusin. *Biochemistry.* 2012; 51:4713–4722. [PubMed: 22510038]
8. Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA, Iordanescu S, So CY, Rosenberg M, Gwynn MN. Identification, Evolution, and Essentiality of the Mevalonate Pathway for Isopentenyl Diphosphate Biosynthesis in Gram-Positive Cocci. *J Bacteriol.* 2000; 182:4319–4327. [PubMed: 10894743]
9. Wilding EI, Kim DY, Bryant AP, Gwynn MN, Lunsford RD, McDevitt D, Myers JE, Rosenberg M, Sylvester D, Stauffacher CV, Rodwell VW. Essentiality, Expression, and Characterization of the Class II 3-hydroxy-3-methylglutaryl Coenzyme A Reductase of *Staphylococcus aureus*. *J Bacteriol.* 2000; 182:5147–5152. [PubMed: 10960099]
10. Feng L, Zhou L, Sun Y, Gui J, Wang X, Wu P, Wan J, Ren Y, Qiu S, Wei X, Li J. Specific Inhibitions of Annonaceous Acetogenins on Class II 3-hydroxy-3-methylglutaryl Coenzyme A Reductase from *Streptococcus pneumoniae*. *Bioorg Med Chem.* 2011; 19:3512–3519. [PubMed: 21550257]
11. Li D, Gui J, Li Y, Feng L, Han X, Sun Y, Sun T, Chen Z, Cao Y, Zhang Y, Zhou L, Hu X, Ren Y, Wan J. Structure-Based Design and Screen of Novel Inhibitors for Class II 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from *Streptococcus Pneumoniae*. *J Chem Inf Model.* 2012; 52:1833–1841. [PubMed: 22725250]
12. Rohdich F, Bacher A, Eisenreich W. Isoprenoid Biosynthetic Pathways as Anti-Infective Drug Targets. *Biochem Soc T.* 2005; 33:785–791.
13. Burg JS, Espenshade PJ. Regulation of HMG-CoA Reductase in Mammals and Yeast. *Prog Lipid Res.* 2011; 50:403–410. [PubMed: 21801748]
14. Istvan ES. Bacterial and Mammalian HMG-CoA Reductases: Related Enzymes with Distinct Architectures. *Curr Opin Struc Biol.* 2001; 11:746–751.
15. Brown MS, Goldstein JL. A Receptor-Mediated Pathway for Cholesterol Homeostasis. *Science.* 1986; 232:34–47. [PubMed: 3513311]

16. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the Complete Program of Cholesterol and Fatty Acid Synthesis in the Liver. *J Clin Invest.* 2002; 109:1125–1131. [PubMed: 11994399]
17. Istvan ES, Deisenhofer J. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. *Science.* 2001; 292:1160–1164. [PubMed: 11349148]
18. Hedl M, Rodwell VW. Inhibition of the Class II HMG-CoA reductase of *Pseudomonas mevalonii*. *Protein Sci.* 2004; 13:1693–1697. [PubMed: 15152097]
19. Taberner L, Rodwell VW, Stauffacher CV. Crystal Structure of a Statin Bound to a Class II Hydroxymethylglutaryl-CoA Reductase. *J Biol Chem.* 2003; 278:19933–19938. [PubMed: 12621048]
20. Bochar DA, Stauffacher CV, Rodwell VW. Sequence Comparisons Reveal Two Classes of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase. *Mol Genet Metab.* 1999; 66:122–127. [PubMed: 10068515]
21. Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl Coenzyme-A (HMG-CoA) Reductases. *Genome Biol.* 2004; 5:248. [PubMed: 15535874]
22. Jordan-Starck TC, Rodwell VW. *Pseudomonas mevalonii* 3-Hydroxy-3-Methylglutaryl-CoA Reductase - Characterization and Chemical Modification. *J Biol Chem.* 1989; 264:17913–17918. [PubMed: 2681185]
23. Lawrence CM, Chi YI, Rodwell VW, Stauffacher CV. Crystallization of Hmg-CoA Reductase from *Pseudomonas mevalonii*. *Acta Crystallogr, Sect D: Biol Crystallogr.* 1995; 51:386–389. [PubMed: 15299306]
24. Istvan ES, Deisenhofer J. The Structure of the Catalytic Portion of Human HMG-CoA Reductase. *Biochim Biophys Acta, Mol Cell Biol Lipids.* 2000; 1529:9–18.
25. Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J. Crystal Structure of the Catalytic Portion of Human HMG-CoA Reductase: Insights into Regulation of Activity and Catalysis. *EMBO J.* 2000; 19:819–830. [PubMed: 10698924]
26. Beedle AS, Munday KA, Wilton DC. The Stereochemistry of Hydrogen Transfer from NADPH Catalysed by 3-hydroxy-3-methylglutaryl-Coenzyme A Reductase from Rat Liver. *Eur J Biochem.* 1972; 28:151–155. [PubMed: 4403574]
27. Dugan RE, Porter JW. Stereospecificity of the Transfer of Hydrogen from Reduced Nicotinamide Adenine Dinucleotide Phosphate in each of the Two Reductive Steps Catalyzed by beta-hydroxy-beta-methylglutaryl Coenzyme A Reductase. *J Biol Chem.* 1971; 246:5361–5364. [PubMed: 4398469]
28. Taberner L, Bochar DA, Rodwell VW, Stauffacher CV. Substrate-Induced Closure of the Flap Domain in the Ternary Complex Structures Provides Insights into the Mechanism of Catalysis by 3-hydroxy-3-methylglutaryl-CoA Reductase. *Proc Natl Acad Sci U S A.* 1999; 96:7167–7171. [PubMed: 10377386]
29. Friesen JA, Lawrence CM, Stauffacher CV, Rodwell VW. Structural Determinants of Nucleotide Coenzyme Specificity in the Distinctive Dinucleotide Binding Fold of HMG-CoA reductase from *Pseudomonas mevalonii*. *Biochemistry.* 1996; 35:11945–11950. [PubMed: 8810898]
30. Hedl M, Taberner L, Stauffacher CV, Rodwell VW. Class II 3-hydroxy-3-methylglutaryl Coenzyme A Reductases. *J Bacteriol.* 2004; 186:1927–1932. [PubMed: 15028676]
31. Bensch WR, Rodwell VW. Purification and Properties of 3-Hydroxy-3-Methylglutaryl Coenzyme-A Reductase from *Pseudomonas*. *J Biol Chem.* 1970; 245:3755–3762. [PubMed: 4321764]
32. Durr IF, Rudney H. Reduction of Beta-Hydroxy-Beta-Methylglutaryl Coenzyme-A to Mevalonic Acid. *J Biol Chem.* 1960; 235:2572–2578. [PubMed: 13818862]
33. Knappe J, Ringelmann E, Lynen F. Über Die Beta-Hydroxy-Beta-Methyl-Glutaryl-Reduktase Der Hefe - Zur Biosynthese Der Terpene .9. *Biochem Z.* 1959; 332:195–213. [PubMed: 14410069]
34. Qureshi N, Dugan RE, Cleland WW, Porter JW. Kinetic-Analysis of Individual Reductive Steps Catalyzed by Beta-Hydroxy-Beta-Methylglutaryl-Coenzyme A Reductase Obtained from Yeast. *Biochemistry.* 1976; 15:4191–4197. [PubMed: 9133]
35. Retey J, Stetten EV, Coy U, Lynen F. A Probable Intermediate in Enzymic Reduction of 3-Hydroxy-3-Methylglutaryl Coenzyme-A. *Eur J Biochem.* 1970; 15:72–76. [PubMed: 4395214]

36. Haines BE, Steussy CN, Stauffacher CV, Wiest O. Molecular Modeling of the Reaction Pathway and Hydride Transfer Reactions of HMG-CoA Reductase. *Biochemistry*. 2012; 51:7983–7995. [PubMed: 22971202]
37. Steussy CNC, CJ, Schmidt T, Wrensford LV, Burgner JB II, Rodwell VW, Stauffacher CV. Coenzyme A as Catalyst. *J Biol Chem*. Submitted.
38. Lawrence CM, Rodwell VW, Stauffacher CV. Crystal-Structure of *Pseudomonas mevalonii* Hmg-CoA Reductase at 3.0 Angstrom Resolution. *Science*. 1995; 268:1758–1762. [PubMed: 7792601]
39. Darnay BG, Wang YL, Rodwell VW. Identification of the Catalytically Important Histidine of 3-Hydroxy-3-Methylglutaryl-Coenzyme-A Reductase. *J Biol Chem*. 1992; 267:15064–15070. [PubMed: 1634543]
40. Jordan-Starck TC, Rodwell VW. Role of Cysteine Residues in *Pseudomonas mevalonii* 3-hydroxy-3-methylglutaryl-CoA Reductase. Site-directed Mutagenesis and Characterization of the Mutant Enzymes. *J Biol Chem*. 1989; 264:17919–17923. [PubMed: 2681186]
41. Wang YL, Darnay BG, Rodwell VW. Identification of the Principal Catalytically Important Acidic Residue of 3-Hydroxy-3-Methylglutaryl Coenzyme-A Reductase. *J Biol Chem*. 1990; 265:21634–21641. [PubMed: 2123872]
42. Veloso D, Cleland WW, Porter JW. Ph Properties and Chemical Mechanism of Action of 3-Hydroxy-3-Methylglutaryl Coenzyme-A Reductase. *Biochemistry*. 1981; 20:887–894. [PubMed: 6783074]
43. Gill JF Jr, Beach MJ, Rodwell VW. Transport of Mevalonate by *Pseudomonas* sp. strain M. *J Bacteriol*. 1984; 160:294–298. [PubMed: 6434521]
44. Gill JF, Beach MJ, Rodwell VW. Mevalonate Utilization in *Pseudomonas* Sp-M - Purification and Characterization of an Inducible 3-Hydroxy-3-Methylglutaryl Coenzyme-A Reductase. *J Biol Chem*. 1985; 260:9393–9398. [PubMed: 4019479]
45. Dugan RE, Katiyar SS. Evidence for Catalytic Site Cysteine and Histidine by Chemical Modification of beta-hydroxy-beta-methylglutaryl-Coenzyme A Reductase. *Biochem Bioph Res Co*. 1986; 141:278–284.
46. Frimpong K, Rodwell VW. The Active-Site of Hamster 3-Hydroxy-3-Methylglutaryl-CoA Reductase Resides at the Subunit Interface and Incorporates Catalytically Essential Acidic Residues from Separate Polypeptides. *J Biol Chem*. 1994; 269:1217–1221. [PubMed: 8288583]
47. Frimpong K, Rodwell VW. Catalysis by Syrian-Hamster 3-Hydroxy-3-Methylglutaryl-Coenzyme-A Reductase - Proposed Roles of Histidine-865, Glutamate-558, and Aspartate-766. *J Biol Chem*. 1994; 269:11478–11483. [PubMed: 7908908]
48. Wrensford LV, Rodwell VW, Anderson VE. 3-Hydroxy-3-methylglutarylthio-Coenzyme A: a Potent Inhibitor of *Pseudomonas mevalonii* HMG-CoA Reductase. *Biochem Med Metab Biol*. 1991; 45:204–208. [PubMed: 1679340]
49. Duncan, C. Analysis of the HMG-CoA Reductase Reaction Mechanism by X-ray Crystallography. Purdue University; 2009.
50. Schwartz B, Vogel KW, Drucekhammer DG. Coenzyme A Hemithioacetals as Easily Prepared Inhibitors of CoA Ester-Utilizing Enzymes. *J Org Chem*. 1996; 61:9356–9361.

Biographies

Brandon E. Haines is a Ph.D. student with Prof. Olaf Wiest in the Department of Chemistry and Biochemistry at the University of Notre Dame. He received his B.S. in chemistry in 2009 from Grand Valley State University in Allendale, MI. His current research focus is employing a combination of computational and crystallographic techniques to investigate the structural and chemical mechanism of HMG-CoA reductase.

Cynthia Stauffacher received her Ph.D. in Physical Chemistry from UCLA and was a postdoctoral fellow at the Rosenstiel Basic Medical Sciences Research Center at Brandeis University. She then joined the Department of Biological Sciences at Purdue University

where she is now a full professor in the Markey Center for Structural Biology. She is the Director of the Chemical and Structural Biology Program of the Purdue Center for Cancer Research and a Fellow of the AAAS

Olaf Wiest received his Ph.D. from the University of Bonn (Germany) and was a Feodor Lynen Postdoctoral Fellow at UCLA before joining the Department of Chemistry and Biochemistry at the University of Notre Dame, where he currently a full professor. He is a Camille Dreyfus Teacher Scholar and a Fellow of the AAAS.

Figure 1.
The Mevalonate Pathway.^{1,6}

Class I	559	735	767	866
Human	VPMATTEGCLVAS	VVREVLKTTTEAM	YIACGQDAAQNVG	GHLVKS ^{HM} IHNR
<i>Saccharomyces cerevisiae</i>	IPMATTEGCLVAS	VVRKVLKSDVSAL	FLALGQDPAQNVE	GHLVQSHMT ^{HN} NRK
Hamster	VPMATTEGCLVAS	VVREVLKTTTEAM	YIACGQDAAQNVG	GHLVRS ^{HM} VHNRS
Rat	VPMATTEGCLVAS	VVREVLKTTTEAM	YIACGQDAAQNVG	GHLVRS ^{HM} VHNRS
Class II	83	267	283	381
<i>Pseudomonas mevalonii</i>	VPLVVE ^{EE} PSIVAA	RAATHNKGIMNGI	IVATGNDWRAVEA	EGIQRG ^{HM} ALHAR
<i>Streptococcus pneumoniae</i>	VPYVTEEPSVVA	RAATHNKGIFNGI	LIATGNDWRAIEA	TGIQQGH ^{HM} MKLQAK
<i>Staphylococcus aureus</i>	VPMVVEEPSVVA	RAATHNKGVMNGI	VLATGNDTRGAEE	EGIQQGH ^{HM} MSLQYK
<i>Enterococcus faecium</i>	IPMATEEPSVIAA	RAATHNKGIMNGI	VAATGNDTRAVSA	EGIQRG ^{HM} MGLQAR

Figure 2.

Sequence alignment of various HMGRs showing the catalytic residues highlighted in red. Conserved residues across classes are highlighted in yellow and conserved residues within classes are highlighted in blue. Human HMGR numbering is shown for the Class I enzymes and *Pm*HMGR numbering is shown for the Class II enzymes.

Figure 3.
General reaction pathway of HMGR.

Figure 4.

The flap domain of *Pm*HMGR is disordered in crystal structures with one or no ligands.³⁸ However, it is ordered over the active site in the presence of both substrate and cofactor.²⁸ a) The *Pm*HMGR crystal structure with no ligands and a disordered flap domain (pdb code 1R7I). b) The nonproductive HMG-CoA/NAD⁺ ternary complex with an ordered flap domain over the active site.

Figure 5. Separated dehydrogenase reactions proposed for the HMGR mechanism. a) aldehyde oxidation to HMG-CoA b) aldehyde oxidation to mevalonate.⁴²

Figure 6.

The mechanism proposed by Frimpong et al. after the catalytic histidine was assigned the role of protonating the CoA thioanion after hemithioacetal decomposition.⁴⁷

Figure 7.
Crystal structure of the nonproductive HMGR ternary complex with HMG-CoA and NAD⁺
(pdb code 1QAX).²⁸

Figure 8.
The mechanism proposed for *PmHMGR* based on crystal structures and discovery of Lys267 in the active site.²⁸

Figure 9.
The mechanism described by Istvan et al. for the human HMGR.²⁴

Figure 10.
The tetrahedral dithiohemiacetal species in the active site of a *PmHMGR* crystal structure

Figure 11. The tetrahedral dithiohemiacetal species in the active site of a *PmHMGR* crystal structure.³⁷

Figure 12.
The revised HMGR mechanism.

Figure 13.
The QM/MM calculated hydride transfer transition structures for the first and second reduction steps of *PmHMGR*.³⁶